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Background - Microvascular damage is one of the first pathological changes in 
systemic sclerosis (SSc). In this study, we investigated the role of Fra-2 (Fos-related 
antigen-2), a transcription factor of the AP-1 (activator protein-1) family, in the 
peripheral vasculopathy of SSc and examined the underlying mechanisms.  
Methods and Results - Expression of Fra-2 protein was significantly increased in 
skin biopsies of SSc patients compared to healthy controls, especially in endothelial 
and vascular smooth muscle cells. Fra-2 transgenic mice developed a severe loss of 
small blood vessels in the skin that was paralleled by progressive skin fibrosis at 
week 12 of age. The reduction of capillary density was preceded by a significant 
increase of apoptosis in endothelial cells at week 9 as detected by 
immunohistochemistry. Similarly, suppression of Fra-2 by siRNA prevented human 
microvascular endothelial cells (HUMECs) from staurosporine-induced apoptosis and 
improved both the number of tubes as well as the cumulative tube lengths in the tube 
formation assay. In addition, cell migration in the scratch-assay and vascular 
endothelial growth factor (VEGF)-dependent chemotaxis in a modified Boyden 
chamber assay were increased after transfection of HUMECs with Fra-2 siRNA, 
whereas proliferation was not affected. 
Conclusions - Fra-2 is present in human SSc and may contribute to the 
development of microvasculopathy by inducing endothelial cell apoptosis and by 
reducing endothelial cell migration and chemotaxis. Fra-2 transgenic mice are a 
promising preclinical model to study the mechanisms and therapeutic approaches of 
the peripheral vasculopathy in SSc. 
 
Key words: peripheral vascular disease – microvascular endothelial cells – systemic 
sclerosis  
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Systemic sclerosis (SSc) is an autoimmune disease of still unknown etiology with 
widespread microvascular damage and progressive fibrosis of the skin and internal 
organs. Among others, infectious agents, tissue injury and hypoxia/oxidative stress 
based on a genetic susceptibility are thought to trigger the onset of the disease. 
Despite the progress in managing complications which occur mostly due to organ 
failure, to date, there is still neither cure nor disease-specific treatment1. 
Microvascular alterations are one of the earliest phenomena in the 
pathophysiology of SSc2. Raynaud’s syndrome and morphological changes on 
nailfold capillaroscopy might occur even years before the onset of fibrosis, 
suggesting a crucial role of the microangiopathy for the overall disease process. 
Microvascular manifestations can be found in different organs. Pulmonary arterial 
hypertension (PAH) is among the leading causes of death in patients with SSc3. The 
peripheral vasculopathy in the skin is characterized by a progressive reduction in the 
number of capillaries resulting in ischemic manifestations such as finger tip ulcers. 
The peripheral vasculopathy has a high morbidity and is a major burden of the 
disease for patients with SSc4. Increased endothelial cell apoptosis can be detected 
in early peripheral vascular lesions and is considered as the earliest pathologic event 
in the development of SSc5. However, the molecular mechanisms initiating and 
perpetuating the peripheral vasculopathy are still unknown. In addition, suitable 
animal models for the peripheral vasculopathy of SSc allowing pathophysiological 
studies and preclinical testing of potential drugs are not available. 
The transcription factor AP-1 is a heterodimeric molecule, composed of 
members of the Jun (c-Jun, JunB, JunD) and the Fos family (c-Fos, FosB, Fra-1, Fra-
2). AP-1 family members are immediate early genes which are induced by a variety 
of stress signals and control subsequent stress responses including cell proliferation, 
apoptosis, inflammation, wound healing and tumorigenesis6. Whereas Jun proteins 
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and the majority of Fos proteins are well characterized, little is known about Fra-2 
and its functions in vivo7, 8. Recently Fra-2 transgenic mice have been characterized 
to develop a severe, proliferative vasculopathy of the lungs resembling pulmonary 
arterial hypertension9. This is followed by progressive lung fibrosis, leading to death 
of the animals at a median age of 17 weeks due to respiratory distress. Thus, this 
animal model links vascular remodelling of the lungs with fibrogenesis and explains 
the link between the two major lung manifestations of SSc. The objective of the 
present study was to investigate the role of Fra-2 for the peripheral microangiopathy 
in Fra-2 tg mice and human SSc.  
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METHODS 
Additional information on methods is provided in the online Data Supplement. 
 
Patients, animals 
 Skin biopsy specimens from SSc patients (n=12) and healthy donors (n=5) 
each) were obtained by punch biopsy. All patients fulfilled the criteria for SSc as 
suggested by LeRoy et al10, and all subjects signed a consent form approved by the 
local institutional review boards. Clinical characteristics are summarized in 
supplementary Table 1. Fra-2 tg mice have been described previously9 and have 
kindly been provided by Erwin F. Wagner.  
 
Histological analysis 
 Skin sections of SSc patients and healthy controls as well as of Fra-2 tg and 
wt mice were fixed in 4% formalin and embedded in paraffin for subsequent analysis 
as described previously11.  
 
Immunohistochemistry for Fra-2, von Willebrand factor (vWF), α-SMA (smooth 
muscle antigen), SM22α (smooth muscle protein 22α) 
Primary and secondary antibodies were used for immunohistochemistry: 
polyclonal rabbit-antibodies against Fra-2 (abcam, Cambridge, UK), vWF (abcam), 
monoclonal mouse-antibodies against α-SMA (Sigma-Aldrich, Buchs, Switzerland), 
monoclonal mouse antibodies against SM22α (abcam); horseradish peroxidase 
(HRP)-labelled secondary goat anti-rabbit and goat anti-mouse antibodies, alkaline 
phosphatase (AP)-conjugated secondary goat anti-mouse antibodies (all from 
Jackson ImmunoResearch, Soham, UK). Negative controls of all stainings are shown 
in the supplementary Fig.1. 
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Detection of apoptosis by TUNEL assay and caspase 3 staining 
 For immunohistochemical detection and quantification of apoptotic cells, we 
employed different assays: the TUNEL (terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labelling) technology using the In Situ Cell Death Detection 
Kit, POD (peroxidase) (Roche, Basel, Switzerland), a fluorescent apoptosis kit 
(ApoTag, Chemicon), and caspase 3 staining with active+pro-caspase 3 antibodies 
(abcam).  
 
Transfection with siRNAs against Fra-2 
 HUMECs were transfected using the HMVEC-L Nucleofector Kit (Amaxa, 
Cologne, Germany) with Fra-2 siRNA as previously described12. HUMECS 
transfected with control siRNAs (scrambled siRNA, Ambion, Darmstadt, Germany) 
were used as negative controls.  
 
Real-time reverse transcription-polymerase chain reaction (RT-PCR) 
 Gene expression was quantified by SYBR Green Real-time PCR using the 
ABI Prism 7500 Sequence Detection System (PE Applied Biosystems, Rotkreuz, 
Switzerland)13.  
 
Western blot analysis for Fra-2 
Nuclear extracts were prepared according to the protocol of Andrews and 
Faller14. Eight g of protein from each sample were separated by 10% SDS-PAGE 
and electrotransferred onto polyvinylidene difluoride (PVDF) membranes (Roth, 
Karsruhe, Germany) as previously described15. Membranes were incubated with 
polyclonal rabbit-anti-human Fra-2 antibodies (abcam) and secondary HRP-
conjugated polyclonal goat anti-rabbit antibodies (DAKO, Hamburg, Germany). For 
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confirmation of equal loading of proteins, the amount of U2AF65 was determined using 
mouse anti-human U2AF65 antibodies (Sigma) and goat anti-mouse antibodies (Dako, 
Glostrup, Denmark).  
 
Microtiter tetrazolium (MTT) assay  
To assess cell proliferation, HUMECs transfected with Fra-2 or scrambled 
siRNA were cultured in 96-well plates and analyzed after 40 h using an automatic 
ELISA plate reader (UV MAX, Molecular Devices, Sunnyvale, CA) at a test 
wavelength of 570nm. 
 
Scratch assay 
HUMECs transfected with Fra-2 siRNA or scrambled siRNA were seeded on 6 
well-plates with or without mitomycin C at a final concentration of 25 μg/ml to control 
for proliferation. After 24h a single uniform scratch was made in each well using a 1 
ml plastic pipet tip. Photographs were taken at 0, 24 and 48h. The distance of the 
wound edges was measured as described recently16. 
 
Chemotaxis-induced migration assay 
 Migration was analyzed using the QCMTM Chemotaxis 96-well cell migration 
assay (Chemicon). HUMECs were transfected with Fra-2 siRNA. VEGF was used as 
chemoattractant. To exclude misleading effects due to proliferation, the experiment 
was repeated in the presence of mitomycin C as described above. After 24h, cell 
lysates were analyzed with a fluorescence plate reader using the 480/520nm filter 
set.  
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Tube formation assay 
 HUMECs transfected with Fra-2 siRNA or scrambled siRNA were cultured in 
6-well plates coated with Matrigel Basement Membrane Matrix (BD Biosciences). 
Cumulative tube length and number of tubes were quantified after 24h as described 
previously17.  
 
Apoptosis assay 
  For induction of apoptosis, HUMECs were treated at different time points with 
increasing concentrations of the protein kinase inhibitor staurosporine (Sigma). 
Untreated HUMECS or transfected with scrambled siRNA served as controls. 
Apoptotic cells were detected by Annexin-V-Fluos/PI staining (Roche) using flow 
cytometry analysis (FACS).  
 
Combined tube formation and apoptosis assay 
 Apoptosis in tube forming HUMECs was analyzed by immunocytochemistry 
using Annexin-V-Fluos (Roche) staining. After transfection with Fra-2 siRNA or 
scrambled siRNA, HUMECs were seeded on double chamber slides coated with 
Matrigel. Twenty-four hours later, tube formation was analyzed, and cells were 
treated with staurosporine. After 2h, cells were incubated with Annexin-V-Fluos 
labelling solution and stained with DAPI (Sigma). The percentage of apoptotic cells 
were calculated as the rate of FITC-positive nuclei out of the total of DAPI stained 
nuclei/high power field (HPF). 
 
Statistical analysis  
The Mann-Whitney-U-test was used for non-related, nonparametric samples. 
Data are expressed as median (Q1=first quartile,Q3=third quartile). P-values <0.05 were 
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considered statistically significant. Power calculation was performed using STATA 
10.0 (StataCorp, College Station, Texas). For the reduction of capillaries at week 12 
as the primary endpoint of the study, with mean±standard deviation 5±2.7 for 
controls, 0.5±0.7 for Fra-2 tg, with alpha set at 0.05 and a given sample size of 5 
animals per group, power was calculated at 95% (ß = 5%). 
 
The authors had full access to the data and take responsibility for its integrity. All 
authors have read and agree to the manuscript as written.  
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RESULTS 
Expression of Fra-2 in vascular smooth muscle cells and endothelial cells of 
Fra-2 tg mice and SSc patients  
In Fra-2 tg mice, the mRNA of the transgene is detectable in various tissues9, 
but the extent and distribution of protein expression varies. Thus, we first aimed to 
characterize the expression pattern of Fra-2 in the skin of Fra-2 tg mice by 
immunohistochemistry. Whereas wt mice did not show a significant expression of 
Fra-2 protein, in Fra-2 tg mice the staining was strongest in vascular structures 
(Fig.1A), and in myofibroblasts (data not shown). 
To propose Fra-2 tg mice as an animal model for the peripheral vasculopathy 
of SSc, Fra-2 should be upregulated in skin fibrosis as well. Therefore, we analyzed 
the expression of Fra-2 in skin sections of SSc patients. Strikingly, in SSc patients 
(Fig.1B) but not healthy controls, the same vascular predominance of Fra-2 
expression was observed. The semiquantitative analysis of skin sections of SSc 
patients demonstrated a prominent expression of Fra-2 in endothelial cells and 
vascular smooth muscle cells in all but one of the 12 SSc patients, whereas only 2 of 
5 healthy controls showed a weak expression in vascular structures (Fig.1C). Fra-2 
was upregulated throughout different disease stages without obvious differences 
between the diffuse and limited SSc (21(20,40) vs. 30(15,41) Fra-2 positive nuclei/HPF). 
To further characterize the vascular cells that overexpressed Fra-2, we 
performed stainings of serial sections or double stainings with antibodies to the 
respective cell markers. In the animal model as well as in SSc patients, the vascular 
expression of Fra-2 was detected in endothelial cells (Fig.2A, C, vWF-positive) and 
vascular smooth muscle cells (Fig.2B, D, α-SMA and SM22α-positive). 
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Fra-2 tg mice display a progressive loss of microvessels  
The reduction of small vessels is a hallmark of the peripheral microangiopathy 
in human SSc. Therefore, we next assessed the vessel density in skin sections of 
Fra-2 tg mice compared to wt mice. In wt mice of different age, there was no evident 
reduction of small dermal arteries and capillaries (Fig.3A). Similarly, Fra-2 tg mice at 
9 weeks of age did not differ from wt mice (Fig.3B). However, starting from week 12, 
a significant decrease in capillary density could be observed in Fra-2 tg mice 
(Fig.3B). Semiquantitative analysis (Fig.3C) revealed 5.0(4,6) capillaries/HPF in wt 
mice compared to only 0(0,1) capillaries/HPF in Fra-2 tg mice (p=0.0003) at the age of 
12 weeks. A similar difference could be detected at 16 weeks with 3.0(2,3) 
capillaries/HPF in wt mice compared to 0.5(0,1.75) capillaries/HPF in the dermis of Fra-
2 tg mice (p=0.0013).  
In contrast to human SSc, dilatation of capillaries was not observed in the skin 
of Fra-2 tg mice, and there was a decreased capillary diameter at week 16 in Fra-2 tg 
mice (supplementary Fig.2). Despite the same expression pattern of Fra-2 in the 
lungs and skin without any obvious difference in the vascular component cell layers 
(supplementary Fig.3A), Fra-2 tg mice did not show a proliferative vasculopathy in 
the skin (supplementary Fig.3B), while they developed simultaneously a severe 
proliferative vasculopathy in the lungs9. These results suggest that the effects of Fra-
2 on the vasculopathy might be organ-dependent. Increased perivascular 
inflammatory infiltrates, which are characteristic of early human SSc, were also 
present in the skin of 9 week old Fra-2 tg mice compared to wt mice (supplementary 
Fig.4), but not in older mice.  
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The onset of microangiopathy in Fra-2 tg mice parallels the development of 
progressive skin fibrosis 
We next aimed to evaluate the temporal relationship between the 
microangiopathy and skin fibrosis in the Fra-2 tg model. In wt mice, no changes of 
dermal thickness could be observed over time (Fig.4A). Similar to the microvascular 
assessment, no differences between wt and Fra-2 tg mice could be detected at 9 
weeks of age. However, Fra-2 tg mice showed a time-dependent increase of dermal 
thickness (Fig.4A lower panel) due to accumulation of extracellular matrix (Fig.4B 
lower panel) starting at 12 weeks (dermal thickness 431(377,529)μm) compared to wt 
littermates (dermal thickness 326(291,354)μm, p=0.0004) (Fig.4A and B, upper panel). 
In Fra-2 tg mice (Fig.4A, B lower panel) a progression of skin thickness could be 
observed at 16 weeks with 522(488,552)μm compared to wt mice with 393(306,485)μm 
(Fig.4A, B upper panel, p=0.002). Fig.4C displays the semiquantitative analysis. 
Taken together, these data show that the microvascular changes paralleled the 
development of skin fibrosis in Fra-2 tg mice.  
  
Apoptosis of endothelial cells precedes the development of microangiopathy 
and fibrosis in Fra-2 tg mice  
Apoptosis of endothelial cells is considered one of the earliest phenomena in 
the development of the microangiopathy in human SSc5. Therefore, we evaluated 
whether apoptosis of endothelial cells might play a role in the observed peripheral 
microangiopathy in Fra-2 tg mice. Analysis of skin sections by TUNEL assay 
demonstrated a higher number of apoptotic cells in the skin of Fra-2 tg compared to 
wt mice (Fig.5A). Semiquantitative analysis of skin sections showed a trend towards 
an increase of apoptotic cells in Fra-2 tg mice already at 9 weeks, which reached 
statistical significance at 12 and 16 weeks compared to wt mice (data not shown).  
 12
To confirm these findings with an independent method, staining with caspase 3 
antibodies was performed as a marker of early apoptosis. Indeed, expression of 
caspase 3 confirmed the TUNEL assay findings with the same time-dependent 
expression pattern (Fig.5A). The increased apoptosis in the skin of Fra-2 tg mice was 
further assessed with an additional TUNEL assay using indirect immunofluorescence. 
Again, Fra-2 tg mice showed increased numbers of apoptotic cells compared to wt 
mice (Fig.5C).  
Moreover, double staining with the endothelial cell marker vWF identified 
endothelial cells as the major apoptotic cell fraction. Notably, in contrast to the total 
cell fraction, endothelial cells in skin sections of Fra-2 tg mice showed a remarkable 
and significant increase of apoptosis already at 9 weeks compared to wt mice 
(55(17,100) TUNEL positive endothelial cells/HPF versus 33(0,75) p=0.01) (Fig.5B). Thus, 
apoptosis of endothelial cells preceded the development of microangiopathy and 
fibrosis in Fra-2 tg mice. These data suggest that similar to human SSc, endothelial 
cell apoptosis could be one of the initiating events for the microangiopathy in this 
model.  
 
Fra-2 knock down reduces apoptosis of human microvascular endothelial cells 
(HUMECs)  
To further confirm the relationship between Fra-2 and increased apoptosis of 
endothelial cells, functional assays with HUMECs were performed. HUMECs 
expressed Fra-2 protein under basal conditions as analyzed by Western blot 
(supplementary Fig.5A). Fra-2 knock down was achieved by transfection of HUMECs 
with specific siRNA (supplementary Fig.5B, C). Twenty-four hours after transfection, 
HUMECs were stimulated with increasing concentrations of staurosporine (1, 2.5, 
5M) at different time points. Treatment with staurosporine led to a dose- and time-
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dependent increase of apoptosis in all cell lines as analyzed by Annexin-V/PI-
staining. While there was no difference in the spontaneous rate of apoptosis, Fra-2 
knock down prevented HUMECs from staurosporine-induced apoptosis. The effect 
was most pronounced after 6 h of treatment, when Fra-2 transfected HUMECs 
showed an average apoptosis of 18.3(14,22)% compared to 30.9(29,33)% in controls 
(p=0.02) (supplementary Fig.6). These data further confirm the link between Fra-2 
expression and apoptosis of microvascular endothelial cells.  
 
Fra-2 knock down improves tube formation by preventing HUMECs from 
apoptosis  
We next aimed to investigate the mechanisms, how Fra-2 induced apoptosis 
of microvascular endothelial cells leads to rarefaction of capillaries. To address this 
question, we performed a tube formation assay comparing cells transfected with Fra-
2 siRNA and scrambled controls. Knock down of Fra-2 in vitro improved the tube 
formation capacity of HUMECs (Fig.6A). The cumulative tube length of cells 
transfected with Fra-2 siRNA was 65(47-79)mm compared to 17.3(11,23)mm from 
controls (p=0.0001), and the number of tubes increased to 46(29,54) after Fra-2 knock 
down compared to 10.5(8-17) in scrambled controls (p=0.002) (Fig.6A). To prove that 
the observed high tube formation capacity of HUMECs after Fra-2 knock down was 
indeed due to prevention from apoptosis, we combined the tube formation and the 
staurosporine-induced apoptosis assay. Apoptotic cells within the forming tubes were 
analyzed by the immunofluorescence-based TUNEL assay. HUMECs transfected 
with scrambled siRNA showed an impaired tube formation capacity with increased 
percentage of apoptotic cells in the forming tubes (Fig.6B). In contrast, Fra-2 knock 
down resulted in intact capillary sprouting with relative low numbers of apoptotic cells 
compared to scrambled controls (Fig.6B). HUMECs transfected with Fra-2 siRNA 
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showed 10.4(9-16)% apoptosis in the tube formation assay compared to 43.5(36-70)% of 
scrambled controls (p=0.002) (Fig.6B). We therefore concluded that the observed 
alteration of tube formation capacity was the result of decreased apoptosis of 
endothelial cells.  
 
Effects of Fra-2 on migration and proliferation of endothelial cells 
To address additional aspects of blood vessel formation, we examined the 
effects of Fra-2 knock down on migration and proliferation of HUMECs. HUMECs 
transfected with Fra-2 siRNA showed an increased migratory capacity in the scratch 
assay. Differences were most pronounced after 48h when HUMECs transfected with 
Fra-2 siRNA had already closed the scratch (p=0.02) (Fig.7A). The effect of Fra-2 on 
migration was underlined by experiments looking at chemotaxis. After transfection 
with Fra-2 siRNA, HUMECs showed an increased VEGF-induced chemotaxis (1.7(1.4-
1.8)fold compared to scrambled control cells, p=0.02) (Fig.7B).  
In contrast to migration, proliferation was not affected by transfection of 
HUMECs with Fra-2 siRNA as analyzed with the MTT assay (data not shown). In 
addition, both the scratch assay and the chemotaxis assay did not reveal different 
results when the proliferation inhibitor mitomycin C was added. This suggests that 
differences in the assays were caused by effects of Fra-2 on migration rather than 
proliferation. 
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DISCUSSION 
To date, the majority of therapeutic efforts in SSc aim to stop the progression 
of fibrosis and the resulting organ failures. However, preventing the onset of fibrosis 
rather than dealing with its complications would be an even more promising 
therapeutic approach. Unfortunately, the initiating factors leading to the increased 
production of extracellular matrix proteins and organ fibrosis in SSc remain unclear. 
Vascular damage has been considered as being important for the early 
pathomechanisms of the disease, as it often occurs even years before the onset of 
fibrosis in the subset of patients with limited cutaneous SSc, and often in parallel with 
the onset of fibrosis in diffuse cutaneous SSc18. However, neither the initiating 
mechanisms leading to the early vascular manifestations nor the link between the 
vasculopathy and organ fibrosis could be established to date, despite a number of 
hypotheses were proposed19.  
The limited progress in the understanding of the early pathomechanisms in 
SSc is in part caused by the lack of human biosamples from early disease stages 
and the lack of appropriate animal models resembling the human vasculopathy. Data 
from larger databases confirm that patients with SSc are often diagnosed late in their 
disease course, when fibrosis is already established and early disease stages have 
been passed20. The UCD 200 chicken model is characterized by an antibody-
mediated vasculopathy, early endothelial cell apoptosis and tissue fibrosis5. 
However, its use is restricted by the high variability in the disease course of individual 
animals, the long generation time of chicken and the challenges in chicken housing. 
Other animal models of SSc do not resemble the vascular features of human SSc or 
are not yet characterized in detail21, 22. Thus, because human samples from early 
disease stages are not available, there is a clear need for feasible animal models of 
the peripheral vasculopathy of SSc.   
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In this study we provide first evidence that Fra-2 tg mice develop several features of 
the human peripheral vasculopathy, which is paralleled by a progressive skin fibrosis 
similar as in patients with SSc. We also provide evidence on several experimental 
levels that apoptosis of endothelial cells cells of peripheral microvessels is among the 
earliest features of enhanced Fra-2 expression both in the in vivo animal model as 
well as in functional in vitro assays with HUMECs. A similar mechanism with 
endothelial cell apoptosis has been proposed for the early peripheral microvascular 
changes in the human disease5. Our experiments extend recent findings by Eferl et 
al9 showing that Fra-2 tg mice develop a severe proliferative pulmonary vasculopathy 
resembling pulmonary arterial hypertension followed by overt lung fibrosis leading to 
premature mortality. Thus, Fra-2 tg mice develop both a peripheral and pulmonary 
vasculopathy followed by organ fibrosis, which are unique features of SSc.   
In contrast to other family members of the Fos and Jun families, Fra-2 is less 
well investigated. Fra-2 is supposed to exert mainly inhibitory effects on its down 
stream targets23, 24, but it has also been shown that its effects depend on various 
factors such as the respective dimerization partner, the cell type or even the cellular 
milieu and cell cycle phase25, 26. Interestingly, it has been shown recently that the 
induction of fibrosis in animal models of chronic inflammation and IL-13/IL-13Rα(2) 
signalling requires dimerization of Fra-2 and c-Jun with subsequent induction of 
TGFß. Indeed, staining of sequential skin sections of Fra-2 tg mice by 
immunohistochemistry revealed strikingly similar expression patterns of c-Jun and 
Fra-2, suggesting that the Fra-2/c-jun AP-1 dimer might also be of importance in Fra-
2 tg mice (data not shown). While we did not address potential stimulators of Fra-2 
expression in the human disease in our study, preliminary experiments indicate that 
the expression of Fra-2 in HUMECs is independent of major cytokines and growth 
factors operative in SSc such as TGFß, PDGF-B and VEGF (data not shown). In 
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addition, our data support the intriguing hypothesis that the pathophysiology of 
internal organ manifestations in SSc are at least in part different from the skin 
disease, because in contrast to the skin, the lungs of Fra-2 tg mice did not show any 
evidence for increased apoptosis as assessed by TUNEL and caspase 3 staining9, 
and there was no proliferative vasculopathy detectable in the skin of Fra-2 tg mice.  
Taken together, we show in this study that Fra-2 tg mice display various 
features of the peripheral vasculopathy of human SSc, with reduction of capillaries 
and early apoptosis of endothelial cells. Furthermore, Fra-2 tg mice combine clinically 
evident peripheral and pulmonary vasculopathy with fibrosis of the skin and internal 
organs, in particular the lungs. We could also show that apoptosis of endothelial cells 
occurs before the manifestation of fibrosis and contributes to the reduction in capillary 
density in later stages of the model. Therefore, Fra-2 tg mice can be proposed as an 
excellent preclinical model that allows to study the link between vasculopathy and 
fibrosis. Fra-2 tg mice also enable to test anti-fibrotic agents and drugs targeting 
vasculopathy simultaneously. Since we provided evidence that Fra-2 is present in 
human SSc, Fra-2 might also represent a promising future target to treat both 
vasculopathy and fibrosis in SSc patients. 
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Figure legends 
Fig.1 Fra-2 expression in the skin of transgenic mice and SSc patients 
Fig.1A: Compared to wt mice, Fra-2 tg mice showed a strong staining for Fra-2 
protein (red) that was most prominent in small blood vessels. 
Fig.1B: The same vascular distribution could be observed in SSc patients but not in 
healthy controls. Magnification x100. Figures are representative examples of 12 SSc 
patients and 5 healthy controls. * indicates significant p-values <0.05. 
Fig.1C: Semiquantitative analysis of Fra-2 expression in SSc skin biopsies 
demonstrated a strong expression of Fra-2 in small vessels in the large majority of 
SSc patients compared to healthy controls.  
 
Fig.2 Fra-2 expression by endothelial cells and vascular smooth muscle cells 
Fig.2A+B: Staining of sequential skin sections of Fra-2 tg mice with the endothelial 
cell marker vWF (violet) and α-SMA (dark blue) for smooth muscle cells revealed that 
Fra-2 protein was most prominently expressed in endothelial cells and vascular 
smooth muscle cells (arrows). The Fra-2 sections were counterstained with 
hematoxylin. Magnification x400. Figures are representative examples of 16 Fra-tg 
mice and 17 wt mice. 
Fig.2C: By staining of sequential sections of SSc patients with vWF (violet) and α-
SMA (green), the expression of Fra-2 protein could be referred to small vessels 
(arrows). Magnification of all slides x400. Figures are representative examples of 12 
SSc patients and 5 healthy controls. 
Fig.2D: Double-staining of sections of Fra-2 tg mice and SSc patients for SM22α as 
an additional marker for smooth muscle cells (light brown/purple cytoplasm; arrows) 
and Fra-2 (dark brown/black nuclei; thick arrows) confirmed that Fra-2 was 
expressed by vascular smooth muscle cells. Magnification of all slides x400. 
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Fig.3 Fra-2 tg mice develop a severe peripheral microangiopathy  
The number of capillaries was determined by immunohistochemical staining for the 
endothelial cell marker vWF (violet) in skin sections of wt (Fig.3A) and Fra-2 tg mice 
(Fig.3B). In Fra-2 tg mice, a severe decrease in the number of capillaries (arrows) 
could be observed, becoming evident from week 12. Magnification of all sections 
x400. Figures are representative examples of 16 Fra-2 tg mice and 17 wt mice. 
Fig.3C: The semiquantitative analysis of the immunohistochemical sections 
confirmed the significant loss of small blood vessels in the dermis of Fra-2 tg mice. * 
indicates significant p-values <0.05. 
 
Fig.4 The onset of microangiopathy in Fra-2 tg mice is paralleled by the 
development of progressive skin fibrosis  
In Fra-2 tg but not wt mice, a time-dependent increase in dermal thickness (Fig.4A) 
could be observed that was apparent from week 12 (HE staining). The difference in 
skin thickness could be referred to accumulation of extracellular matrix in Fra-2 tg 
mice by staining with picrosirius red (Fig.4B). Arrows show the initial dermal 
thickness at week 9 to illustrate time-dependent changes. Magnification x100. Fig.4C: 
This graph summarizes the results of the semiquantitative analysis of the skin 
sections. * indicates significant p-values < 0.05. Figures are representative examples 
of 16 Fra-2 tg mice and 17 wt mice. 
 
Fig.5 Apoptosis of endothelial cells precedes the development of the peripheral 
microvasculopathy.  
Fig.5A: Compared to wt littermates (upper panel), a higher number of apoptotic cells 
could be observed in the dermis of Fra-2 tg mice (lower panel, dark brown and black 
nuclei) as assessed by TUNEL assay or staining for caspase 3. Magnification x100.  
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Fig.5B: Semiquantitative analysis revealed a significantly higher percentage of 
TUNEL-positive endothelial cells in the dermis of Fra-2 tg compared to wt mice, 
starting from week 9. * indicates significant p-values <0.05. 
Fig.5C: By using an additional TUNEL assay with indirect immunofluorescence, 
apoptotic nuclei were stained with FITC (green) and counterstained with DAPI (blue). 
In Fra-2 tg mice (middle) a higher number of FITC-positive cells could be detected 
compared to wt mice. The adjacent picture shows the respective conventional 
TUNEL staining to allow better assessment of the structures (right). Experiments 
were done in triplicate. Magnification x200. Figures are representative examples of 
16 Fra-2 tg mice and 17 wt mice. 
 
Fig.6 Fra-2 knock down improves tube formation of HUMECs  
Fig.6A: Compared to controls transfected with scrambled siRNA the knock down of 
Fra-2 in HUMECs resulted in a remarkable increase of tube formation capacity. 
Pictures were taken 24h after transfection. The semiquantitative evaluation of the 
tube formation assay demonstrated that both the cumulative tube length and the 
number of tubes were significantly improved after Fra-2 knock down. Experiments 
were done in triplicate. * indicates significant p-values <0.05. 
Fig.6B: To assess whether apoptosis of HUMECs might contribute to the observed 
improvement in capillary sprouting after Fra-2 knock down, we combined the tube 
formation assay with an apoptosis assay. Apoptosis was induced by staurosporine 
after transfection with Fra-2 or scrambled siRNA and examined by 
immunocytochemistry using Annexin V-staining. In scrambled controls fewer cells 
were visible, because most of them had detached due to apoptosis, and the majority 
of remaining cells (DAPI, blue staining) were apoptotic (FITC, green staining). Fra-2 
knock down resulted in unaffected tube formation with higher number of attached 
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cells (DAPI, blue) and a much lower percentage of apoptotic cells (FITC, green). The 
semiquantitative analysis (right) confirmed that Fra-2 knock down prevented 
HUMECs from staurosporine-induced apoptosis with a significantly lower percentage 
of apoptotic cells in HUMECs transfected with Fra-2 siRNA. Experiments were done 
in triplicate. * indicates significant p-values <0.05. 
 
Fig.7 Fra-2 knock down improves the migration capacity of HUMECs 
Fig.7A: In the scratch assay, HUMECs transfected with Fra-2 siRNA migrated faster 
into the scratch, thus leading to an earlier closing of the wound at 48h. 
Fig.7B: Effects of Fra-2 on the migration of endothelial cells were confirmed by 
analysis of VEGF-induced chemotaxis in a modified Boyden chamber assay with 
increased chemotaxis after knock down of Fra-2 in HUMECs compared to scrambled 
controls. Experiments were done in triplicate. * indicates significant p-values <0.05. 
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